Search results
So the link cant be posted, but search it on youtube: Tales from the Trenches: Paul Edick, CEO of Xeris. They have a bunch of other things in the pipeline. Excluding any licensing potential from their technology, their pipeline peak global sales is close to $2bn annually.
Xeris Biopharma announced a CEO succession plan effective August 1, under which Paul Edick will be retiring from his day-to-day operational and chairman role at Xeris after more than seven years with the company.
Jul 8, 2024 · Xeris Biopharma Holdings (NASDAQ:XERS) announced a CEO succession plan with John Shannon taking over from Paul Edick on August 1, 2024. Edick, the current CEO and chairman, will retire from his roles after more than seven years with the company. Shannon, currently Xeris’ president and COO, will succeed Edick as CEO and join the board of ...
Xeris Biopharma (NASDAQ:XERS) said Paul Edick will be retiring from his day-to-day operational and chairman role after more than seven years with the company. The firm has appointed COO, John...
May 9, 2019 · This summer, the company plans to commercialize its first product, which delivers the life-saving hormone glucagon to people with diabetes who experience a severe drop in blood sugar. Below are some of our key takeaways from Paul’s talk. An ‘accidental’ leap into healthcare.
Jul 8, 2024 · Xeris Biopharma Holdings President and Chief Operating Officer John Shannon will move into the CEO role Aug. 1, replacing Paul Edick. Edick, 68, who took the reins at Xeris in 2017, will...
Jul 8, 2024 · Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a...
